Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selbex in Acute Gastritis and Gastric Ulcer
NCT01190657Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of teprenone in acute gastritis, gastric ulcer and chronic gastritis (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Endoscopic results of ulcer lesion at 56 days and Total effective rate at 56 days. Started May 2010; status: completed.
02
Drugs
teprenone
03
Conditions
acute gastritisgastric ulcerchronic gastritis
Beyond the preview
Go deeper on NCT01190657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01190657.